EarlySense, an Israeli company which develops contact free monitoring solutions, announced its active involvement in the National Coalition to Promote Continuous Monitoring of Patients on Opioids.
An opioid is any chemical that resembles morphine or other opiates in its pharmacological effects.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
The AAMI Foundation, with the support of key industry partners including EarlySense, is launching a multiyear initiative in effort to increase awareness of the need to continuously monitor patients on opioids in an effort to recognize respiratory depression earlier and in an attempt to save lives.
With its international headquarters in Israel, and US headquarters in Waltham, MA, the EarlySense System is currently installed in hospitals and rehabilitation centers in USA, Europe, Asia and Australia.
A significant portion of respiratory depression events occur in postoperative patients receiving opioid analgesics and sedative for pain. Opioid Induced respiratory depression continues to be a serious hospital acquired adverse event. However, continuous monitoring solutions, including central surveillance, may enhance clinician’s ability to identify patients at risk earlier. The earlier a clinician can identify the risk of a patient, the lower the chance of respiratory depression which lessens the risk of complications including patient death.
The EarlySense System continuously monitors the two most important predictors: heart rate and respiratory rate, thus allowing opportunities for early intervention. The system uses a sensor placed under the bed’s mattress which never comes into contact with the patient. There are no leads or cuffs to connect to the patient who has complete freedom of movement and is not burdened by any cumbersome attachments of sensors, electrodes and cuffs.
“We have seen numerous cases in which the EarlySense System has helped to detect Opioid Induced Respiratory Depression. Low respiratory rates detected by EarlySense ultimately led to timely detection and intervention to prevent respiratory depression caused by narcotic treatment, ” said Dr. Eyal Zimlichman, The Center for Patient Safety Research and Practice, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA, and Deputy Director and VP of Quality Management at Sheba Medical Center.
“There is a clear and immediate need to continuously monitor ventilation for patients on opioid treatment within the hospital. EarlySense is certainly emerging as a solution that can provide exactly that with mounting evidence relating to low frequency and accuracy of alerts as well as financial return on investment, ” continued Zimlichman.